Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSMYC Trial: Sequential BATZEN and ZENZA in mCRPC
NCT06922318Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2025
- Primary completion
- Aug 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ZEN3694 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Clinical/radiographic progression free survival at 2 years and Prostate specific antigen-Progression free survival at 2 years. Started Aug 2025; status: recruiting.
02
Drugs
ZEN3694
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06922318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922318.